Key result
Pravastatin therapy in normocholesterolemic patients with coronary sclerosis reduced expected two-year healthcare costs compared to no cholesterol-lowering drugs (¥182,532 vs ¥224,444 per patient) and yielded a cost-effectiveness ratio of ¥2,766,994 per event-free year.
Why the study?
Does pravastatin therapy provide a cost-effective strategy for secondary prevention of coronary heart disease in normocholesterolemic patients?
Population
120 patients aged 20-69 years with a history of coronary heart disease and baseline serum total cholesterol…
Comparison
Pravastatin 10 mg/day vs No cholesterol-lowering drugs
Design
Randomly assigned, open-labeled
Follow-up
2 years
Authors
Loading...
May support cost savings with pravastatin in Japanese normocholesterolemic patients; leaves open generalizability and need for randomized confirmation.
RCT (n=120)
Open-label
Randomly assigned
Does pravastatin therapy provide a cost-effective strategy for secondary prevention of coronary heart disease in normocholesterolemic patients?
Absolute Risk Reduction: 5.4
Absolute Event Rate: 3.7% vs 9.1%
Absolute Risk Reduction: 5.4%
Number Needed to Treat: 19
p-value: p=0.11
Pravastatin therapy for secondary prevention of coronary heart disease in normocholesterolemic patients is cost-effective from a health insurance perspective in Japan.
Sato et al. (2004) conducted an RCT in Coronary heart disease (secondary prevention) (n=120). Pravastatin vs. No cholesterol-lowering drugs was evaluated on Recurrence of coronary heart disease (ARR 5.4%, p=0.11). Pravastatin therapy in normocholesterolemic patients with coronary sclerosis reduced expected two-year healthcare costs compared to no cholesterol-lowering drugs (¥182,532 vs ¥224,444 per patient) and yielded a cost-effectiveness ratio of ¥2,766,994 per event-free year.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: